Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
517 hedge funds and large institutions have $26.3B invested in Alexion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 212 increasing their positions, 190 reducing their positions, and 54 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 190
3% more capital invested
Capital invested by funds: $25.4B → $26.3B (+$811M)
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
3% less funds holding
Funds holding: 533 → 517 (-16)
18% less call options, than puts
Call options by funds: $111M | Put options by funds: $135M
20% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$783M |
| 2 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$185M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$167M |
| 4 |
State Street
Boston,
Massachusetts
|
+$165M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$106M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$1.32B |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$169M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$153M |
| 4 |
GE
General Electric
Evendale,
Ohio
|
-$115M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$72.6M |
ALXN Hedge Fund Activity: Q3 2016 in Review
517 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2016, worth a combined $26.3B — up 3.2% from $25.4B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of ALXN and 43 opened new positions — a net loss of 11 holders — while 190 trimmed existing stakes and 212 added.
The largest buyer was Fidelity Investments, adding an estimated $783M. The largest seller was Capital Research Global Investors, cutting an estimated $1.32B.
- 517 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2016, down from 533 in Q2 2016.
- Funds reported $26.3B of Alexion Pharmaceuticals stock for Q3 2016, up 3.2% quarter-over-quarter.
- 43 funds opened new Alexion Pharmaceuticals positions in Q3 2016 and 54 closed out, a net change of -11 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2016 was Fidelity Investments, an estimated $783M added.
- The largest Alexion Pharmaceuticals seller in Q3 2016 was Capital Research Global Investors, an estimated $1.32B sold.
Based on aggregated 13F filings for Q3 2016.